key: cord-0770933-3lybodeg
authors: Hsu, Caroline M.; Weiner, Daniel E.; Aweh, Gideon; Miskulin, Dana C.; Manley, Harold J.; Stewart, Carol; Ladik, Vlad; Hosford, John; Lacson, Edward C.; Johnson, Douglas S.; Lacson, Eduardo
title: COVID-19 Infection Among US Dialysis Patients: Risk Factors and Outcomes From a National Dialysis Provider
date: 2021-01-17
journal: Am J Kidney Dis
DOI: 10.1053/j.ajkd.2021.01.003
sha: 4338be33fb3f750866942e10104cdf1d7e6f5ef9
doc_id: 770933
cord_uid: 3lybodeg

RATIONALE & OBJECTIVE: During the COVID-19 pandemic, patients receiving maintenance dialysis are a highly vulnerable population due to their comorbidities and circumstances that limit physical distancing during treatment. This study sought to characterize the risk factors for and outcomes following COVID-19 infection in this population. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Maintenance dialysis patients in clinics with at least one patient with a positive test for SARS-CoV-2 from February to June 2020, treated by a mid-size national dialysis provider. PREDICTORS: Demographics, dialysis characteristics, residence in a congregate setting, comorbid conditions, measures of frailty, and use of selected medications. OUTCOMES: COVID-19 defined as having a positive SARS-CoV-2 test and all-cause mortality among those with COVID-19. ANALYTICAL APPROACH: Logistic regression analyses to identify clinical characteristics associated with COVID-19and risk factors associated with mortality among patients following COVID-19. RESULTS: 438/7948 (5.5%) maintenance dialysis patients developed COVID-19. Male sex, Black race, in-center dialysis (vs. home dialysis), treatment at an urban clinic, residence in a congregate setting, and greater comorbidity were associated with contracting COVID-19. Odds of COVID-19 was 17-fold higher for those residing in a congregate setting [OR = 17.10 (95% CI 13.51, 21.54)]. Of the 438 maintenance dialysis patients with COVID-19, 109 (24.9%) died. Older age, heart disease, and markers of frailty were associated with mortality. LIMITATIONS: No distinction between symptomatic and asymptomatic SARS-CoV-2 positivity, with asymptomatic screening limited by testing capacity during this initial COVID-19 surge period. CONCLUSIONS: COVID-19 is common among patients receiving maintenance dialysis, particularly those residing in congregate settings. Among maintenance dialysis patients with COVID-19, mortality is high, exceeding 20%.

Dialysis dependent patients with end-stage kidney disease are particularly vulnerable to coronavirus (COVID)-19, the disease caused by the SARS-CoV-2 virus. Maintenance dialysis patients average 65 years old and typically have multiple medical comorbid conditions, including diabetes, obesity, and uremia induced impaired immunity, all of which increase their risk for poor outcomes should they develop COVID-19. [1] [2] [3] [4] [5] [6] As a more socioeconomically disadvantaged group than the general population, including residence in more densely populated urban areas, they are at higher risk of acquiring SARS-CoV-2. 7, 8 Additionally, most dialysis patients cannot practice effective physical distancing due to the need for in-center hemodialysis and associated transportation, as well as frequent reliance on social support and caregivers for assistance with daily activities or medication management. Confluence of these factors potentiates risk in the many who reside in long-term care facilities. [9] [10] [11] [12] Studies in China, Italy, the UK, New York, and southern California show that maintenance dialysis patients with COVID-19 experience higher mortality and more severe disease compared to the general population. [13] [14] [15] [16] [17] [18] [19] In the latest United States Renal Data Systems Annual Report, approximately 524,000 patients were receiving dialysis in the country as of 2017, constituting a large at-risk population. 11 By June of 2020, the Centers for Medicare & Medicaid Services reported a COVID-19 prevalence of 3.8% in the dialysis population, 20 but further characterization is needed. Given the lack of national, generalizable data on COVID-19 in the vulnerable maintenance dialysis population, we characterized risk factors for COVID-19 among dialysis patients treated by a medium-sized, national dialysis organization. Additionally, among those diagnosed with COVID-19, we characterized risk of and risk factors for death.

J o u r n a l P r e -p r o o f Methods Dialysis Clinic Inc. (DCI) is a national not-for-profit dialysis provider caring for more than 15 ,000 maintenance dialysis patients at 260 outpatient dialysis clinics in 29 states. All dialysis patients diagnosed with COVID-19 in DCI clinics between February 17, 2020 and June 1, 2020 are included in this retrospective cohort study, with outcomes ascertained through August 31, 2020. This initial 15-week period reflects the early surge of COVID-19 in the United States. We sought to describe our outpatient dialysis provider experience and determine risk factors for COVID-19 as well as for all-cause death within 90 days of a COVID-19 diagnosis. To mitigate bias from geographic imbalance of COVID-19 spread, we only included all patients from clinics with at least one diagnosed COVID-19 case in the analysis. Patients being treated with dialysis for acute kidney injury were excluded.

Based on contemporary practices, SARS-CoV-2 infection status was assessed via nasopharyngeal or oropharyngeal swabs sent locally for reverse transcriptase polymerase chain reaction (RT-PCR) testing that was approved by the FDA under Emergency Use Authorization or, if unavailable locally, through the DCI Labs contracted vendor beginning in April 2020 (using either the Hologic Panther Fusion®, Marlborough, MA, USA or Cobas SARS-CoV-2 Assay, Roche Diagnostics, Indianapolis, IN, USA). Although facility and regional practices differed, positive test results were captured regardless of whether a patient was assessed in the dialysis clinic, at a testing center, or at a hospital. In accordance with CDC guidance at the time, 21 prior to each treatment, patients were identified for testing by the dialysis staff through screening for recent exposure to a known COVID-19 patient, travel history to an endemic area, and/or symptoms of cough, dyspnea, fever, sore throat, and unexplained oxygen saturation J o u r n a l P r e -p r o o f <92%. Of note, only one DCI clinic performed routine RT-PCR screening of COVID-19 status in dialysis patients regardless of screening results. All patients with a positive SARS-CoV-2 test were defined as having COVID-19. Patients without a positive SARS-CoV-2 test were considered to be without COVID-19. Procedures regarding isolation varied by center and whether COVID-19 was suspected or confirmed, reflecting local resources and availability of isolation rooms. All clinics either cohorted patients with COVID-19 together, often on a dedicated COVID-19 shift either at that facility or at a nearby clinic, or treated those with suspected or confirmed COVID-19 in isolation rooms with dedicated staff. Universal masking policies were adopted in all clinics by the end of March.

Demographic, comorbid, and clinical information including emergency department and/or hospitalization events and death reports (CMS form 2746) were obtained from DCI's proprietary outpatient electronic health record. Patient characteristics obtained from the electronic health record included age, sex, race, ethnicity, vintage, dialysis modality, treatment at an urban or rural clinic, use of central venous catheter, living in a congregate setting at the time of diagnosis (e.g. nursing home, skilled nursing facility, or rehabilitation facility), body mass index, the number of comorbid conditions as well as specific comorbid conditions (e.g. diabetes mellitus, hypertension, congestive heart failure, atherosclerotic heart disease, cerebrovascular disorders, other cardiac diseases, chronic obstructive pulmonary disease, peripheral vascular disease, cancer), history of limb amputation, wheelchair use, need for assistance to perform activities of daily living, alcohol abuse, drug abuse, tobacco use, vaccination for influenza during the 2019- cases; clinics with no COVID-19 cases through June 1, 2020 were excluded from the comparator group. This was chosen to minimize the influence of geographic factors in models because COVID-19 prevalence varied greatly across the country during the study period. Quantitative J o u r n a l P r e -p r o o f variables were presented as means and standard deviations as well as medians. For simplicity, we represented age as decades between 50 and 80 years. For albumin, we categorized based on severe hypoalbuminemia <3.5 g/dL, mild to moderate hypoalbuminemia 3.5 to 3.9 g/dL, and normal at ≥4.0 g/dL. In addition to age, sex, and race, variables that were pre-specified a priori, only candidate variables significant at p<0.1 were included in multivariable analyses. Similarly, logistic regression models were constructed among patients with COVID-19 to assess patient characteristics related to mortality from COVID-19. Subgroup analyses were performed by stratifying on residence in a congregate setting. For consistency in comparisons, multivariable analysis of these subgroups incorporated the same variables used in the multivariable analysis of the aggregate. Statistical significance was defined as p ≤ 0.05.

This retrospective de-identified evaluation was performed under exemption for informed consent through the DCI "Chronic Kidney Disease Quality Improvement and Clinical Outcomes" evaluation process, through the Western Institutional Review Board (WIRB, www.wirb.com).

All statistical analyses were performed using SAS v.9.4 (www.sas.com). We used t-test, analysis of variance (ANOVA) and chi square tests to compare data for most continuous, categorical and dichotomous variables, respectively, by COVID-19 status; the exceptions are use of the Kruskal-Wallis test for vintage and body mass index, and use of the Fisher's exact test for assistance with ADL.

A total of 438 maintenance dialysis patients were diagnosed with COVID-19 during the 15-week study period, approximately 3% of 15,200 patients treated in 260 DCI clinics. Not all states and DCI clinics were exposed to COVID-19 during this early surge; the true denominator included J o u r n a l P r e -p r o o f patients from 96 clinics from 22 states with at least 1 affected patient, comprising 52% of all DCI patients (Supplemental Figure 1) . Therefore, these patients represented 5.5% (438/7,948) of the dialysis population in impacted clinics. Comparing to non-infected patients in these clinics, dialysis patients with COVID-19 were older, more likely to be Black, more likely to be treated with in-center hemodialysis, more likely to be treated at an urban clinic, more likely to use respiratory inhalers, and more likely to reside in a congregate setting (e.g. nursing home).

Additionally, those with COVID-19 had a higher burden of comorbidity, with higher prevalence of cardiovascular diseases and of diabetes along with more patients who required assistance with activities of daily living and/or use of a wheelchair (Table 1) .

In multivariable models, risk factors associated with COVID-19 infection in maintenance dialysis included male sex, Black race, treatment at an urban clinic, residence in a congregate setting, greater number of comorbid conditions, and carrying a diagnosis of atherosclerotic heart disease and diabetes, while individuals treated with home dialysis were less likely to have COVID-19 ( Table 2) .

All 438 dialysis patients diagnosed with COVID-19 were either followed to death or censored at with unknown site of death and 2 at home), and another 9 patients were hospitalized 30 days or more after diagnosis. Three of these 9 patients were admitted due to COVID-19, while the other 6 received inpatient care for various medical conditions including vascular access issues. All 128 surviving outpatients were considered COVID-recovered as of the end of follow-up.

Among the 296 patients who went to the ED or hospital, including 25 patients who were diagnosed while hospitalized, over half the patients were tested upon arrival to the ED or on the day of inpatient admission, with diagnosis based on this test. Thus while the average time from COVID-19 onset to hospitalization was 2.8 ± 5.9 days (range 1-28 days), the median was on the first day. The overall length of stay after COVID-19 diagnosis for all hospitalized patients was 10.8 ± 10.7 days, with a median LOS of 8 (IQR: 4, 14) days. Among patients who survived to discharge, length of stay was 11.1 ± 11.7 days, with a median LOS of 8 (IQR: 4, 13) days.

Among the 109 patients who died, the mean time to death was 16.7 ± 17.1 days, with a median of 11 days (IQR: 5.5, 22 days); one patient died in the ED. Approximately half the deaths had COVID-19 mentioned specifically as the primary or secondary cause of death, with additional notes in the electronic health records for all but six patients indicating that COVID-19 may have contributed to death; of these 6, 3 cases had a date of death with no documented information surrounding the death. Immediate cause of death was most often attributed to pulmonary causes (51.9%), followed by cardiac (9.3%) and a combination of cardiac and pulmonary causes (7.4%).

There were 8.3% of cases that specifically mentioned infection/sepsis and 2.8% due to J o u r n a l P r e -p r o o f hemorrhage. There were 20 deaths (18.5%) with the primary cause described only as cardiopulmonary arrest without further information or no information surrounding death circumstances recorded at all. Overall, 10 patients withdrew from dialysis (6 residing in a nursing home, 3 while in the hospital, and 1 at home), 9 of whom received hospice care prior to death.

Characteristics of patients who died compared to those who survived are shown in Table 3 .

Older patients had higher mortality, particularly those over 80 years old. Comorbidity related to CHF, hypertension, and other cardiovascular diseases as well as PVD, low albumin, and wheelchair use were more prevalent in patients who died. In multivariable models, older age became strongly associated with death, with increased risk in each decade after age 50, along with PVD, CHF, hypertension, and wheelchair use remaining significantly associated with mortality risk ( Table 4 ).

In subgroup analysis with stratification by residence in a congregate setting, 199/7198 (2.8%) of patients in non-congregate settings had COVID-19, compared to 239/750 (31.9%) among residents of congregate settings. Of those with COVID-19, mortality was 22.1% and 27.2% respectively (Supplemental Tables 1a, 1b) . Multivariable analysis of the subgroups showed risk factors for COVID-19 to be similar to risk factors identified in aggregate analysis (Supplemental Tables 2a, 2b ).

Maintenance dialysis patients are at high risk of developing COVID-19 and, among those with COVID-19, 90-day mortality approaches 25%. Of note, the current study extended outcome J o u r n a l P r e -p r o o f follow-up to 90 days, compared to most initial reports that covered only early and short-term outcomes. Among dialysis patients, key risk factors for COVID-19 include residence in a long term care facility, Black race, male sex, diabetes, receipt of in-center as compared to home dialysis, and treatment at an urban dialysis center. In dialysis patients who develop COVID-19, older age, hypertension, congestive heart failure, and peripheral vascular disease as well as wheelchair use, are associated with higher risk of death.

Studies have shown close interrelation of socioeconomic status with health outcomes, further exacerbated by systemic racial biases. 22 The ability to maintain physical distancing -through low household density, working from home, or accepting a loss of income -is a matter of privilege and more often the territory of more affluent communities. In contrast, urban areas of high density, which tend to have a greater non-White population, reflect communities in which a pandemic is more likely to take hold, 8 highlighted by a higher prevalence of medical comorbid conditions. That our study shows worse outcomes with non-White race, more comorbid conditions, and treatment at urban dialysis centers reflects this tangle of many factors. Of note, unlike in the general population, Hispanic ethnicity was not associated with either risk of acquiring COVID-19 or risk of mortality in patients with COVID-19. It is possible that the locations of DCI clinics with COVID-19 patients generally had a lower proportion of people who identify as Hispanic or that missing ethnicity data impacted results.

Among dialysis patients, those also residing in a congregate setting had over 17-fold higher rate of COVID-19 compared to those residing independently, a pattern that, although commented on, has not been well quantified in national studies. 23, 24 In congregate residences such as group J o u r n a l P r e -p r o o f homes and nursing facilities, the capacity to isolate COVID-positive patients is often limited, staffing may be stretched as employees fall ill, and staff members carry infectious risk to the community when they leave the facility. There may be a role for universal screening in such congregate settings, particularly when at least one case is identified. 25 Moreover, patients living in congregate settings are often older and more likely to be frail; the association of mortality with markers of frailty such as age, PVD, and mobility shows that COVID-19 in the congregate setting is all the more damaging.

Reflecting these factors, communities with dense urban populations, Black and Hispanic neighborhoods, and high numbers of nursing home residents have the greatest need for support during this pandemic. Measures such as expanded testing, community education, promoting capacity for telemedicine and financial support to facilitate physical distancing would reduce transmission. Because a large proportion of dialysis patients derive from these communities, nephrologists have a responsibility to advocate for better disease containment and greater relief for these communities. Furthermore, compared to other disadvantaged groups, dialysis patients almost constantly interface with the healthcare system; accordingly public health departments can and should coordinate with dialysis providers to provide interventions such as expanded testing and possibly vaccination prioritization.

The mandatory congregate settings and the associated commutes can create additional exposure risk for the majority of dialysis patients, as demonstrated by the increased risk associated with incenter dialysis relative to home dialysis. Patients performing home dialysis tend to be younger and healthier than patients treated by in-center hemodialysis. 11 Similar to other studies, 17, 19 about 60% of COVID-positive dialysis patients have been hospitalized, translating to a need for adequate resource planning for in-hospital dialysis equipment, consumables, and staffing to minimize strain, particularly given the associated system strain with the high incidence of acute kidney injury requiring dialysis among critically ill COVID-19 patients. With admissions averaging eleven days' duration in an already-frail J o u r n a l P r e -p r o o f population, a number of patients may be expected to need rehabilitation; therefore coordination among hospitals, dialysis centers, rehabilitation facilities and long-term care facilities is critical to avoid medical errors and readmissions. In early studies, COVID-19 survivors have presented a spectrum of persistent pulmonary dysfunction, and they are expected to have a high prevalence of post-intensive care syndrome, which encompasses reduced physical, cognitive, and mental health after critical illness. 27 Therefore maintenance dialysis patients who survive COVID-19 may benefit from interdisciplinary post-hospitalization care. Lastly, this study and others demonstrate that mortality exceeds 20% among maintenance dialysis patients. [17] [18] [19] 28, 29 Therefore discussions around advance care planning should be considered to avoid aggressive medical therapy when it is incongruent with one's life goals and values; this is particularly true of those with advanced age and with other indicators of frailty, which were associated with mortality in our study. The appropriate planning for and implementation of palliative care and hospice is critical in this population, particularly with the devastating impact of acute illnesses like COVID-

Our study of COVID-19 in the outpatient dialysis setting uses a large population derived from a national dialysis provider with longitudinal patient follow-up for outcomes. We nevertheless acknowledge its limitations. It focuses on observational data acquired from the dialysis provider, rendering specific details surrounding in-hospital events less available. Second, very limited testing availability, particularly in March through June 2020, may have resulted in underestimation of COVID-19 cases and misclassification of deaths. Third, given the extensive comorbid condition burden in dialysis patients with COVID-19, determining the cause of death in this population remains somewhat subjective, and we have restricted analyses to all-cause J o u r n a l P r e -p r o o f death. Fourth, we excluded dialysis clinics with no COVID-19 cases to facilitate comparison between COVID and non-COVID patients; while this may result in other biases being introduced into models, this restriction critically prevents comparisons with geographic regions where COVID-19 incidence was very low during this early pandemic surge, therefore making COVID-19 cases unlikely in the dialysis clinic. Lastly, because our study defined all patients with a positive SARS-CoV-2 test as having COVID-19, we did not distinguish asymptomatic carriers from those with symptomatic disease; currently, SARS-CoV-2 vaccines' impact on asymptomatic carriage and transmission is unknown, so this distinction will need greater investigation and scrutiny as vaccinations occur.

In conclusion, dialysis patients are at high risk of COVID-19, with 5.5% of patients diagnosed with COVID-19 in facilities with at least one COVID-19 case during the first 3 months of the pandemic. In-center dialysis, residence in a long-term care facility and Black race are all major risk factors associated with COVID-19, suggesting that the ability to physically distance is 

Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease

COVID-19 in Immunocompromised Hosts: What We Know So Far

Immune Dysfunction and Risk of Infection in Chronic Kidney Disease

COVID-19 and Racial/Ethnic Disparities

COVID-19, Poverty, and Race in Greater Chicago: An Ecological Analysis

Hemodialysis and COVID-19: An Achilles' Heel in the Pandemic Health Care Response in the United States

COVID-19 in a Long-Term Care Facility

Annual Data Report: Epidemiology of Kidney Disease in the United States

End-stage renal disease in nursing homes: a systematic review

Clinical Characteristics of and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan

A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection

Serologic Detection of SARS-CoV-2 Infections in Hemodialysis Centers: A Multicenter Retrospective Study in Wuhan, China

Epidemiology of COVID-19 in an Urban Dialysis Center

COVID-19 Infection in ESKD: Findings from a Prospective Disease Surveillance Program at Dialysis Facilities in New York City and Long Island

Presentation and Outcomes of Patients with ESKD and COVID-19

COVID-19 and Survival in Maintenance Dialysis

Preliminary Medicare COVID-19 Data Snapshot

Updated Guidance on Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19)

COVID-19 and African Americans

COVID-19 outcomes among people with intellectual and developmental disability living in residential group homes in New York State

COVID-19 Infection Risk Among Hemodialysis Patients in Long-term Care Facilities

Facility-Wide Testing for SARS-CoV-2 in Nursing Homes -Seven

Mitigating Risk of COVID-19 in Dialysis Facilities

A clinic blueprint for post-COVID-19 RECOVERY: Learning from the past, looking to the future

Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients

Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int

1%)

Note: Data are reported as mean ± standard deviation (median) or %. Age is reported in years and dialysis duration (vintage) in months. ACEi, angiotensin converting enzyme inhibitor

congestive heart failure; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease

ADL, activities of daily living. Race and ethnicity are independent of each other

142 Not Hospitalized* (32.4%) of COVID+ (32.1%) Overall Death Rate: 24

Deaths/438 Infected Patients)